Nektar Therapeutics (NKTR) Debt to Equity (2011 - 2020)

Nektar Therapeutics' Debt to Equity history runs 10 years deep, the most recent figure standing at $0.39 for Q1 2020.

• In Q1 2020, Debt to Equity rose 159.22% year-over-year to $0.39; the TTM figure through Mar 2020 stood at $0.39 (up 159.22% YoY), while the FY2019 annual figure was $0.18, up 25.15% from the prior year.
• Debt to Equity was $0.39 for Q1 2020 at Nektar Therapeutics, up from $0.18 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $72.16 in Q2 2017 to a low of -$880.47 in Q1 2016.
• Historically, Debt to Equity has averaged -$46.97 across 5 years, with a median of $0.17 in 2019.
• The sharpest annual moves came in 2016 and 2017: Debt to Equity sank 54551.96% in 2016, then soared 1267.67% in 2017.
• A 5-year view of Debt to Equity shows it stood at $2.76 in 2016, then increased by 1.06% to $2.79 in 2017, then plunged by 94.85% to $0.14 in 2018, then climbed by 25.15% to $0.18 in 2019, then soared by 118.17% to $0.39 in 2020.
• The last three Debt to Equity figures came in at $0.39 (Q1 2020), $0.18 (Q4 2019), and $0.17 (Q3 2019), per Business Quant data.